Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20

Benzinga Newsdesk www.benzinga.com Positive 67.6%

Neg 0% Neu 0% Pos 67.6%

Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $18 to $20.